Survodutide Hits 17% Weight Loss in Phase 3: Obesity Drug Race Heats Up
· health
Boehringer Ingelheim's obesity candidate Survodutide delivered roughly 17% average weight loss in its Phase 3 readout.
Daily Issue
#obesity
Stories tagged obesity.
Daily Issue
Stories tagged obesity.
· health
Boehringer Ingelheim's obesity candidate Survodutide delivered roughly 17% average weight loss in its Phase 3 readout.